Fig. 8
From: cRGD-based MRI imaging-enhanced nanoplatform helps DOX target pancreatic cancer
(A) Experimental design of the efficacy of cHDG@MSN in treating subcutaneous tumor model of pancreatic cancer, (B) Changes in body weight of nude mice in each group. (C) Graph of the effect of tumor treatment after treatment, (D) Final mean tumor weight after 15 days of treatment, (E) Changes in tumor volume.
